Hisanobu Kaiya

Hisanobu Kaiya

Auto-generated profile, based on publicly available information

Hisanobu Kaiya

Panic Disorder Research Center, Warakukai Medical Corporation, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2022 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
BBBorwin Bandelow
Borwin Bandelow
CAChrister Allgulander
Christer Allgulander
DBDavid S. Baldwin
David S. Baldwin
DCDaniel Lucas da Conceição Costa
Daniel Lucas da Conceição Costa
DDDamiaan Denys
Damiaan Denys
JZJoseph Zohar
Joseph Zohar
This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive–Compulsive and Po...

28 July 2022 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
BBBorwin Bandelow
Borwin Bandelow
CAChrister Allgulander
Christer Allgulander
DBDavid S. Baldwin
David S. Baldwin
DCDaniel Lucas da Conceição Costa
Daniel Lucas da Conceição Costa
DDDamiaan Denys
Damiaan Denys
JZJoseph Zohar
Joseph Zohar
Aim: This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive–Compulsive and Posttraumatic Stress Disorders which was published in 2002 and revised in 2008. Method: A consensus panel of 34 international experts representing 22 countries developed recommendations based on efficacy and acceptability of the treatments. In this version, not only medications but also psychotherapies and other non-pharmacological interventions were evaluated, applying the same rigorous methods that are standard for the assessment of medication treatments. Result: The present paper (Part II) contains recommendations based on published randomised controlled trials (RCTs) for the treatment of OCD (n = 291) and PTSD (n = 234) in children, adolescents, and adults. The accompanying paper (Part I) contains the recommendations for the treatment of anxiety disorders. For OCD, first-line treatments are selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioural therapy (CBT). Internet-CBT was also superior to active controls. Several second-line medications are available, including clomipramine. For treatment-resistant cases, several options are available, including augmentation of SSRI treatment with antipsychotics and other drugs. Other non-pharmacological treatments, including repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS) and others were also evaluated. For PTSD, SSRIs and the SNRI venlafaxine are first-line treatments. CBT is the psychotherapy modality with the best body of evidence. For treatment-unresponsive patients, augmentation of SSRI treatment with antipsychotics may be an option. Conclusion: OCD and PTSD can be effectively treated with CBT and medications.

21 January 2017 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
MSMihoko Shimada-Sugimoto
Mihoko Shimada-Sugimoto
TOTakeshi Otowa
Takeshi Otowa
TMTaku Miyagawa
Taku Miyagawa
TUTadashi Umekage
Tadashi Umekage
YKYoshiya Kawamura
Yoshiya Kawamura
TSTsukasa Sasaki
Tsukasa Sasaki
Panic disorder (PD) is considered to be a multifactorial disorder emerging from interactions among multiple genetic and environmental factors. To date, although genetic studies reported several susceptibility genes with PD, few of them were replicated and the pathogenesis of PD remains to be clarified. Epigenetics is considered to play an important role in etiology of complex traits and diseases, and DNA methylation is one of the major forms of epigenetic modifications. In this study, we performed an epigenome-wide association study of PD using DNA methylation arrays so as to investigate the possibility that different levels of DNA methylation might be associated with PD. The DNA methylation levels of CpG sites across the genome were examined with genomic DNA samples (PD, N = 48, control, N = 48) extracted from peripheral blood. Methylation arrays were used for the analysis. β values, which represent the levels of DNA methylation, were normalized via an appropriate pipeline. Then, β values were converted to M values via the logit transformation for epigenome-wide association study. The relationship between each DNA methylation site and PD was assessed by linear regression analysis with adjustments for the effects of leukocyte subsets. Forty CpG sites showed significant association with PD at 5% FDR correction, though the differences of the DNA methylation levels were relatively small. Most of the significant CpG sites (37/40 CpG sites) were located in or around CpG islands. Many of the significant CpG sites (27/40 CpG sites) were located upstream of genes, and all such CpG sites with the exception of two were hypomethylated in PD subjects. A pathway analysis on the genes annotated to the significant CpG sites identified several pathways, including “positive regulation of lymphocyte activation.” Although future studies with larger number of samples are necessary to confirm the small DNA methylation abnormalities associated with PD, there is a possibility that several CpG sites might be associated, together as a group, with PD.

29 March 2020 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
MYMaria Yamasaki
Maria Yamasaki
TMTakashi Makino
Takashi Makino
Seik-Soon KhorSeik-Soon Khor
Seik-Soon Khor
HTHiromi Toyoda
Hiromi Toyoda
TMTaku Miyagawa
Taku Miyagawa
Katsushi TokunagaKatsushi Tokunaga
Katsushi Tokunaga
Background: Copy number variants (CNVs) have been reported to be associated with diseases, traits, and evolution. However, it is hard to determine which gene should have priority as a target for further functional experiments if a CNV is rare or a singleton. In this study, we attempted to overcome this issue by using two approaches: by assessing the influences of gene dosage sensitivity and gene expression sensitivity. Dosage sensitive genes derived from two-round whole-genome duplication in previous studies. In addition, we proposed a cross-sectional omics approach that utilizes open data from GTEx to assess the effect of whole-genome CNVs on gene expression. Methods: Affymetrix Genome-Wide SNP Array 6.0 was used to detect CNVs by PennCNV and CNV Workshop. After quality controls for population stratification, family relationship and CNV detection, 287 patients with narcolepsy, 133 patients with essential hypersomnia, 380 patients with panic disorders, 164 patients with autism, 784 patients with Alzheimer disease and 1280 healthy individuals remained for the enrichment analysis. Results: Overall, significant enrichment of dosage sensitive genes was found across patients with narcolepsy, panic disorders and autism. Particularly, significant enrichment of dosage-sensitive genes in duplications was observed across all diseases except for Alzheimer disease. For deletions, less or no enrichment of dosage-sensitive genes with deletions was seen in the patients when compared to the healthy individuals. Interestingly, significant enrichments of genes with expression sensitivity in brain were observed in patients with panic disorder and autism. While duplications presented a higher burden, deletions did not cause significant differences when compared to the healthy individuals. When we assess the effect of sensitivity to genome dosage and gene expression at the same time, the highest ratio of enrichment was observed in the group including dosage-sensitive genes and genes with expression sensitivity only in brain. In addition, shared CNV regions among the five neuropsychiatric diseases were also investigated. Conclusions: This study contributed the evidence that dosage-sensitive genes are associated with CNVs among neuropsychiatric diseases. In addition, we utilized open data from GTEx to assess the effect of whole-genome CNVs on gene expression. We also investigated shared CNV region among neuropsychiatric diseases.

25 February 2016 in Human Genome Variation
Verified
Journal Article
Open access
MSMihoko Shimada-Sugimoto
Mihoko Shimada-Sugimoto
TOTakeshi Otowa
Takeshi Otowa
TMTaku Miyagawa
Taku Miyagawa
Seik-Soon KhorSeik-Soon Khor
Seik-Soon Khor
YOYosuke Omae
Yosuke Omae
TSTsukasa Sasaki
Tsukasa Sasaki
We herein report an association between TMEM132D and panic disorder (PD) in a Japanese population, evaluating the effects of HLA-DRB1*13:02, which we previously reported as a susceptibility genetic factor for PD. SNPs in TMEM132D showed significant associations with PD in subjects without HLA-DRB1*13:02 (rs4759997; P=5.02×10−6, odds ratio=1.50) but not in those with the HLA allele. TMEM132D might have a role in the development of PD in subjects without HLA-DRB1*13:02.

30 November 2020 in Anxiety Disorder Research
Verified
Journal Article
Open access
PDF file
HKHisanobu Kaiya
Hisanobu Kaiya
SNShota Noda
Shota Noda
ETEri Takai
Eri Takai
IFItaru Fukui
Itaru Fukui
MMMina Masaki
Mina Masaki
FMFusaka Minami-Kaiya
Fusaka Minami-Kaiya
Anxious-depressive attack (ADA) is a recently proposed symptom cluster consisting of sudden intense feelings of distressing emotions with no direct psychological cause. It is characterized by intrusive rumination of mainly regretful memories accompanied by a violent emotional storm, resulting in countermeasures including acting out behaviors. ADA seems to manifest in various anxiety and affective disorders as well as some personality disorders, but may have been overlooked. A previous study showed that patients with ADA were more socially anxious and more depressive than those without ADA, regardless of their diagnoses. Social anxiety disorder (SAD) is one of such disorders with a high prevalence of ADA (44.4%). According to clinical reports, patients with SAD appear hypersensitive to rejection or criticism. The present study examined the relationships among ADA, social anxiety, depression and rejection sensitivity (RS) in patients diagnosed with SAD using structural equation modeling (SEM). Findings showed that RS directly significantly affects ADA, as well as indirectly via depression and social anxiety. Depression had a direct, positive effect on ADA, whereas social anxiety had an indirect effect on ADA via depression. The present study suggests that RS may contribute to the development of ADA in patients with SAD.